10x Genomics: Surprise Profitability Temporary—It's Still A Welcome Sign (TXG)

Group 1 - The article discusses the initial coverage of 10x Genomics (NASDAQ: TXG) with a pessimistic outlook due to expected persistent losses through at least 2028 despite a strong balance sheet [1] - The analyst highlights a focus on finding underappreciated companies that can return value to investors, indicating a contrarian investment philosophy [1] Group 2 - There are no stock, option, or similar derivative positions held by the analyst in any mentioned companies, nor plans to initiate such positions within the next 72 hours [2] - The article expresses the author's own opinions without receiving compensation from any company mentioned [2]